Mark H Greene


Affiliation: National Institutes of Health
Country: USA


  1. Sherman M, Piedmonte M, Mai P, Ioffe O, Ronnett B, Van Le L, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014;32:3275-83 pubmed publisher
    ..BRCA1/2 mutation, postmenopausal status, and abnormal preoperative CA-125 and/or TVU were associated with cancer detection at RRSO. These data can inform management decisions among women at high risk of ovarian/tubal cancer. ..
  2. Pathak A, Adams C, Loud J, Nichols K, Stewart D, Greene M. Prospectively Identified Incident Testicular Cancer Risk in a Familial Testicular Cancer Cohort. Cancer Epidemiol Biomarkers Prev. 2015;24:1614-21 pubmed publisher
    ..Men at high TGCT risk might benefit from tailored risk stratification and surveillance strategies. ..
  3. Greene M, Mai P. The fallopian tube: from back stage to center stage. Cancer Prev Res (Phila). 2015;8:339-41 pubmed publisher
  4. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, et al. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015;17:61 pubmed publisher
    ..This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects. ..
  5. Silvestri V, Barrowdale D, Mulligan A, Neuhausen S, Fox S, Karlan B, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016;18:15 pubmed publisher
    ..e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management. ..
  6. Mai P, Piedmonte M, Han P, Moser R, Walker J, Rodriguez G, et al. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;145:122-129 pubmed publisher
  7. Pereira L, Pineda M, Rowe W, Fonseca L, Greene M, Offit K, et al. The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies. BMC Genet. 2007;8:68 pubmed
  8. Greene M, Kratz C, Mai P, Mueller C, Peters J, Bratslavsky G, et al. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer. 2010;17:R109-21 pubmed publisher
    ..All five loci are involved in normal testicular development and/or male infertility. These genetic data provide a novel insight into the genetic basis of FTGCT, and an invaluable guide to future TGCT research. ..